SciRhom’s Post

🔬 Mercia Ventures has continued its support into Invizius by leading a £950,000 funding round. The Edinburgh-based biotech company is developing breakthrough treatments for patients on dialysis and the latest investment will enable the company to prepare for the next stage of clinical trials of its H-Guard product and comes in the run-up to a Series B investment round early next year. 📈 H-Guard addresses the inflammatory responses that patients suffer during dialysis which can cause life-threatening complications including damage to organs and the cardiovascular system. Mercia Ventures, who has supported Invizius since 2018, was supported by Calculus Capital, Syensqo, The University of Edinburgh's Old College Capital and Scottish Enterprise. Read more (link in comments) ⏬ #EIS #Investment #VC #VentureCapital #Scotland

👏 Former SETsquared Scale-Up Programme member, iFAST Diagnostics, has announced the closure of its successful $6.5m (£5m) seed round, allowing them to bring their rapid antimicrobial susceptibility testing (AST) test to the UK market as soon as early 2025. While traditional AST methods require 48 to 72 hours, the iFAST system reduces this testing time to under three hours - delivering the potential to improve patient outcomes whilst making sure that patients receive the right treatment at the right time. To support this mission, iFAST has seen significant investment through its recent oversubscribed round, led by KHP Ventures, the first NHS-anchored venture fund, alongside existing investors QantX, UKI2S (Managed by Future Planet Capital, Kadmos, and several angel investors. New investors, EInk, Raw Ventures, and OKG Capital also contributed to the round. Get the full story 👉 https://lnkd.in/gDYNxZvf #MedTech #Medicine #AMR #AntibioticResistance

Curious about how PharmNovo’s first-in-class, phase II ready lead asset may transform the treatment of neuropathic pain and even combat the opioid crisis creating new treatment of opioid withdrawal syndrome / opioid use disorder? Come and listen to the presentation by our CEO Per von Mentzer and talk with us.

Cassava Sciences (SAVA) opened today down -85% from almost $27/share to $4/share, representing their largest ever daily loss since IPO in 2000. SAVA is essentially a one drug company and shareholders have been heavily reliant on simufiliam - SAVA’s hopeful cure for Alzheimer’s - successfully completing clinical trials. This morning Cassava Sciences announced a Phase 3 study of its Alzheimer's treatment simufilam didn't meet co-primary, secondary and exploratory biomarker endpoints (meaning it failed). SAVA subsequently confirmed they would discontinue funding their Alzheimer’s research program, so they’re effectively worth whatever cash & cash equivalents they own, which I suspect is under $4/share. OVOM Research, TradingView #Research #Economy #Markets #Macro #Equities

Congratulations, Steven, on an outstanding job representing FBB Biomed at the Des Moines Iowa Angel Investor Summit! You truly shined in showcasing the incredible potential of our work, leaving a lasting impression on investors and innovators alike. Now, let’s keep the momentum going and wrap up this seed-round equity raise so we can take FBB Biomed to infinity and beyond! #dementia #alzheimers #venturecapital #angelinvestor #cancer#hivaids  #bioOS #biotechnology #diagnostics#innovation #technology #management #startups #liquidbiopsy#neurodegenerativediseases #multiplesclerosis #parkinsonsdisease #alzheimersdisease #longhaulers #longcovid #humangenome #onetestonelife#longevity #artificialintelligence #rna #rnaseq #personalizedprevention #PersonalizedMedicine#ClinicalResearch #COVID19 #Parkinsons #climatechange #functionalmedicine

WE.DO.HEALTHCARE🚀🚀 I am pleased to share this to show once again that we advise innovative #Biomedical, #MedTech and #PharmaTech start-ups in a highly regulated area, in order to make a small contribution to even better medicine. ➡️ Periprosthetic infections lead to numerous avoidable medical malpractice cases. A periprosthetic joint infection is an infection of the peri-implant tissue of an artificial joint implanted in the body. The number of joint replacement surgeries has been increasing for years due to the ageing population and the increasing demands of patients who want to remain active into old age. InfectoTest GmbH is thus another example of an innovation that can make a significant contribution. Dr. Marc-André Rousseau

#fundingalert 💼Company: Karius 💰Funding: $100Million ⚡Round: Series C 👥Investors:  Khosla Ventures, 5AM Ventures , Gilde Healthcare, Seventure Partners, Softbank Vision Fund 2, General Catalyst, HBM Healthcare Investments AG, Blue Water Life Sciences, Innovation Endeavors, Waycross Ventures, and others. Karius Inc., a global leader in liquid biopsy for infectious diseases, harnesses metagenomics, next-generation sequencing, and artificial intelligence (AI) to help enhance the precision and speed of pathogen diagnosis. it’s Test®is , used in over 400 healthcare institutions–including 90+ transplant centers and 40+ children’s hospitals across the United States–identifies more than 1,000 pathogens, including viruses, bacteria, fungi, and parasites from a single blood draw typically within a day of sample receipt. The funding enables it to address increasing demand from healthcare providers to expand access to the Karius Test beyond the hospital setting. Additionally, it will support research into the broader health implications of Karius’ microbial cell-free DNA technology beyond infectious diseases. Alec Ford, Alexander A. Morgan, MD PhD, Joep Muijrers, Tim Blauwkamp, Sivan Bercovici, Brad Perkins,Steve Malaska, William Q., Meredith Reichert Read more - https://lnkd.in/gWnGtGTC To share your startup story write us on - contact@startuprise.io #Karius #metagenomics #DNAtechnology #healthtechtechnology #pathogen #healthtech #funding #fundingnews #news #startup #startupnews #startuprise

📯 Axoltis Pharma's team is very proud to be among the #PrixGalien USA Award nominees for "Best Startup" !   This year marks the tenth anniversary of The Galien Foundation and Business France recognizing global innovators in the "Best Startup" category. This partnership supports global healthcare startups by offering visibility on the American stage and connecting them with major players in the industry in the U.S. and Canada. Axoltis aims to expand its current panel of collaborations with academic labs and with potential pharma partners in the world, especially in North America to explore the broad range of indications of its patented lead product #NX210c.   NX210c could change the game in the treatment of neurodegenerative diseases. Aside to a neuroprotective effect, its main property is the recovery of the blood brain barrier integrity which is impaired in a broad range of diseases. Axoltis has just launched a phase II clinical trial in Amyotrophic Lateral Sclerosis (#ALS), where the #BBB is impaired since the early stages of the disease. ALS is a fatal disease with a huge unmet medical need.. #PrixGalienUSA #BusinessFranceNorthAmerica #FrenchHealthcare #ChooseFrance

Great news from Ascenion GmbH and showing that #technology & #transfer are key to such successes, filling and supporting the value added innovation chains at the front end!

Join Us on the Ground Floor of Transforming Neurologic Diagnostics Thank you, Loyal VC, for the opportunity to present at your showcase! We are incredibly proud to have a venture partner like Loyal VC, whose dedication to innovation and support for early-stage companies like FBB Biomed is truly invaluable. Loyal VC is ranked among the top ten of PitchBook’s 2024 list of most active early-stage investors, alongside powerhouses like Sequoia and FJ Labs. Their partnership not only fuels our mission to transform neurologic diagnostics but also provides the network and expertise we need to thrive in this next phase of growth. In this four-minute video, I share our pitch deck for FBB Biomed’s current equity financing round, priced at the seed level. This investment will enable us to transition into full commercial operations with Verici Dx, access SSBCI/ Iowa Economic Development Authority matching non-dilutive funds, and launch our groundbreaking Research Use Only tests. Powered by artificial intelligence, these tests are designed for early-adopter clinicians eager to revolutionize the management of neurologic diseases. If you’re a qualified Reg D investor, this is your chance to join an extraordinary journey. Contact me at info@fbbbio.com to learn more and help shape the future of precision and personalized diagnostics! 🚀 #dementia #alzheimers #venturecapital #angelinvestor #cancer #hivaids  #bioOS #biotechnology #diagnostics #innovation #technology #management #startups #liquidbiopsy #neurodegenerativediseases #multiplesclerosis #parkinsonsdisease #alzheimersdisease #longhaulers #longcovid #humangenome #onetestonelife #longevity #artificialintelligence #rna #rnaseq #personalizedprevention #PersonalizedMedicine #ClinicalResearch #COVID19 #Parkinsons #climatechange #functionalmedicine https://lnkd.in/efSEu7Pp